Recent News

• 06.12.2025 - Saving Time, Saving Lives: Natural Killer Cells and Cancer Therapy
• 05.27.2025 - Natural Killer Cells Are Revolutionizing Cancer Therapy
• 05.14.2025 - Could Curing Cancer Cost 99% Less in Asia?
• 04.29.2025 - Stem Cell Banking Market To Reach $16 Billion USD by 2031
• 04.28.2025 - CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
• 04.15.2025 - 2024 Was a Good Year for CAR T-cell Therapies… 2025 Promises to Be Better
• 03.26.2025 - A Testament to The Science 18 Years in Remission After CAR T-Cell Therapy
• 03.13.2025 - CAR T-Cell Therapy is Very Expensive… But There Are Ways to Reduce Costs
• 02.27.2025 - The Market for Regenerative Medicine to Hit $235.98 Billion by 2032
• 02.12.2025 - Trump’s Massive Investment in AI Cancer Vaccines

Recent Filings

• 05.16.2025 - EX-99.1 EX-99.1
• 05.16.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.28.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 04.28.2025 - EX-99.1 EX-99.1
• 03.24.2025 - 144 Report of proposed sale of securities
• 03.24.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.14.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 03.04.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors